Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 1, 2001, Pages 72-79

  Veldhuis, J D ^a,c   Pincus, S M ^d   Garcia Rudaz, M C ^b   Ropelato, M G ^b   Escobar, M E ^b   Barontini, M ^b  

^a NATIONAL SCIENCE FOUNDATION   (United States)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ESTRADIOL; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADOLESCENT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEEDBACK SYSTEM; FEMALE; FLUOROMETRY; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; NIGHT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TESTOSTERONE RELEASE;

ADOLESCENT; ANDROSTENEDIONE; CIRCADIAN RHYTHM; FEMALE; HUMANS; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; REFERENCE VALUES; TESTOSTERONE; TIME FACTORS;

EID: 0035145810     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.1.72     Document Type: Article

References (74)

1. A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome
2. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome
3. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach
4. Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome
5. A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both both basal and pulsatile LH in adolescents with polycystic ovarian syndrome
6. Increased luteinizing hormone and α-subunit secretion in women with hyperandrogenic anovulation
7. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea
8. Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays
9. Circulating luteinizing hormone pulse frequency in women with polycystic ovary syndrome
10. Detection of functional ovarian hyperandrogenism in women with androgen excess
11. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features
12. Neuroendocrine aspects of polycystic ovary syndrome
13. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls
14. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: Indirect evidence for partial gonadotroph desensitization
15. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome
16. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome
17. Preponderance of basic isoforms of serum luteinizing hormone (LH) is associated with the high bio/immuno ratio of LH in healthy women and women with polycystic ovarian disease
18. Studies of the nature of 17-hydroxyprogesterone, hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism
19. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: Assessment of neuroendocrine and androgen dynamics
20. Adrenal and ovarian contributions to the elevated plasma free androgen levels in hirsute women
21. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: Relevance to the developmental phase of polycystic ovarian syndrome
22. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist
23. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease
24. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca
25. Transvaginal ultrasound imaging, histopathology and endocrinopathy in patients with polycystic ovarian syndrome
26. Interactive stimulation by LH and insulin of the steroidogenic acute regulatory (StAR) protein and 17α-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells
27. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
28. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in women with the polycystic ovary syndrome
29. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
30. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
31. Inhibitory effect of octreotide on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome
32. A biomathematical model of time-delayed feedback in the human male hypothalamic-pituitary-Leydig cell axis
33. Approximate entropy as a measure of system complexity
34. Quantification of hormone pulsatility via an approximate entropy algorithm
35. Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males
36. Hormone pulsatility discrimination via coarse and short time sampling
37. Estrogen and testosterone, but not a non-aromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: Evidence from pubertal pathophysiology and sex-steroid hormone replacement
38. Randomness and degrees of irregularity
39. Orderliness of hormone release patterns: A complementary measure to conventional pulsatile and circadian analyses
40. Insulin resistance in polycystic ovary syndrome
41. Greater disorderliness of ACTH and cortisol release accompanies pituitary-dependent Cushing's disease
42. Disruption of the young-adult synchrony between luteinizing hormone release and oscillations in follicle-stimulating hormone, prolactin, and nocturnal penile tumescence (NPT) in healthy older men
43. Neuroendocrine mechanisms by which selective Leydig-cell castration unleashes increased pulsatile LH release in the human: An experimental paradigm of short-term ketoconazole-induced hypoandrogenemia and deconvolution-estimated LH secretory enhancement
44. Primary gonadal failure in men selectively amplifies the mass of follicle stimulating hormone (FSH) secreted per burst and increases the disorderliness of FSH release: Reversibility with testosterone replacement
45. Mechanisms of ACTH neurosecretory reactivity to abrupt withdrawal of glucocorticoid negative feedback in healthy men: Pulsatile, nyctohemeral, and entropic responses
46. Greater signal regularity may indicate increased system isolation
47. Reduction of intrinsic negative-feedback regulation of neuroendocrine axes increases the approximate entropy (serial irregularity) of the pituitary hormone release process for TSH, GH, and LH
48. Effects of age on the irregularity of LH and FSH serum concentrations in women and men
49. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release
50. Increased episodic release and disorderliness of prolactin secretion in both micro- and macroprolactinomas
51. Increased disorderliness and amplified basal and pulsatile aldosterone secretion in patients with primary aldosteronism
52. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotropic IGF-I, and IGF-binding protein responses to a three-day intravenous growth-hormone-releasing-hormone (GHRH) pulsatile infusion
53. Disruption of the pulsatile and entropic modes of insulin release during an unvarying glucose stimulus in elderly individuals
54. Females secrete growth hormone with more process irregularity than males in both human and rat
55. Assessing temporal coupling between two, or among three or more, neuroendocrine pulse trains: Cross-correlation analysis, simulation methods, and conditional probability testing
56. Aging alters feedforward and feedback linkages between LH and testosterone in healthy men
57. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome
58. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease
59. Serum luteinizing hormone profile during the menstrual cycle in polycystic ovarian syndrome
60. Polycystic ovary syndrome: Evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone
61. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation
62. The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women
63. Hormonal effects of flutamide in young women with polycystic ovary syndrome
64. 1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease
65. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease
66. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects
67. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women
68. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment
69. Tripartite neuroendocrine activation of the human growth-hormone (GH) axis in women by continuous 24-hour GH-releasing peptide (GHRP-2) infusion: Pulsatile, entropic, and nyctohemeral mechanisms
70. A preliminary study of pulsatile GnRH administration in hypogonadal men with end-stage renal disease
71. Neuroendocrine aberrations in women with functional hypothalamic amenorrhea
72. Insulin enhancement of luteinizing hormone and follicle stimulating hormone release by cultured pituitary cells
73. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells
74. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome